Lantheus Holdings (LNTH) Common Equity (2014 - 2026)
Lantheus Holdings (LNTH) posted quarterly Common Equity of $1.2 billion for Q1 2026, up 4.13% year-over-year from $1.2 billion in Q1 2025, and up 11.24% quarter-over-quarter from $1.1 billion in Q4 2025.
Lantheus Holdings (LNTH) Common Equity (2014 - 2026) Analysis & Trends
Lantheus Holdings (LNTH) has reported Common Equity for 13 consecutive years, with $1.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 4.13% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $1.2 billion (up 4.13% YoY), while the FY2025 annual figure was $1.1 billion, changed 0.16% from the prior year.
- Common Equity advanced to $1.2 billion in Q1 2026 per LNTH's latest filing, from $1.1 billion in the prior quarter.
- Across five years, Common Equity topped out at $1.2 billion in Q1 2026 and bottomed at $445.5 million in Q1 2023.
- Historically, Common Equity has averaged $863.1 million across 5 years, with a median of $945.5 million in 2024.
- Annual changes were most pronounced in 2023 — Common Equity decreased 13.63% — and 2024, when it jumped 112.23%.
- Lantheus Holdings' Common Equity stood at $447.1 million in 2022, then soared by 82.47% to $815.9 million in 2023, then jumped by 33.35% to $1.1 billion in 2024, then grew by 0.16% to $1.1 billion in 2025, then grew by 11.24% to $1.2 billion in 2026.
- Business Quant data shows LNTH's Common Equity at $1.2 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 4.05 Bn |
| 10 | Lantheus Holdings | 6.54 Bn | 5.94 Bn | 241.86 Mn | 1.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.31 Bn |
| Mar 31, 2026 | 1.21 Bn |
| Dec 31, 2025 | 1.09 Bn |
| Sep 30, 2025 | 1.12 Bn |
| Jun 30, 2025 | 1.17 Bn |
| Mar 31, 2025 | 1.16 Bn |
| Dec 31, 2024 | 1.09 Bn |
| Sep 30, 2024 | 1.18 Bn |
| Jun 30, 2024 | 1.03 Bn |
| Mar 31, 2024 | 945.54 Mn |
| Dec 31, 2023 | 815.89 Mn |
| Sep 30, 2023 | 698.76 Mn |
| Jun 30, 2023 | 552.65 Mn |
| Mar 31, 2023 | 445.52 Mn |
| Dec 31, 2022 | 447.15 Mn |
| Sep 30, 2022 | 638.05 Mn |
| Jun 30, 2022 | 567.33 Mn |
| Mar 31, 2022 | 515.85 Mn |
| Dec 31, 2021 | 464.44 Mn |
| Sep 30, 2021 | 499.34 Mn |